Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesInventiva S.A.

Inventiva S.A.

PortfolioPortfolio WatchlistWatchlist
Company price
3.24 GBX 0.14 ( 4.35%)
Last update at 2026-10-27T16:29:00Z
VOLUME
14386
Market Cap
84.70M

Momentum Score

…

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.24
Low
3.41
High
52 Week Price Range
2.60
Low
6.19
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.10
Dividend Yield
-
Revenue TTM
7.93M
Revenue Per Share
0.04
Gross Profit TTM
7.93M
Debt / Equity
-0.51
ROE
-1642.76%
Net Debt
-42.23M
ROCE
5530.44%
Diluted EPS TTM
-1.27

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -183.90M -109.82M -54.29M -49.27M -33.62M
Net income -184.21M -110.43M -54.27M -49.63M -33.62M
Selling general administrative 15.41M 13.85M 12.07M 10.32M 7.57M
Selling and marketing expenses 1.69M 1.75M 2.57M 0.36M 0.57M
Gross profit 9.20M 17.50M 17.82M 7.48M 4.42M
Ebit -97.56M -104.57M -57.16M -52.12M -32.62M
Ebitda -96.69M -102.04M -56.31M -51.27M -31.77M
Depreciation and amortization 0.86M 2.53M 0.84M 0.86M 0.85M
Operating income -97.56M -102.71M -57.16M -52.12M -32.62M
Other operating expenses 112.28M 120.19M 72.79M 57.69M 39.04M
Interest expense 12.18M 5.22M - 0.00M 0.00M
Interest income - - - - 3.89M
Income tax expense 0.31M 0.61M 0.02M 0.36M -
Total revenue 14.72M 17.48M 18.81M 8.50M 5.26M
Total operating expenses 106.76M 120.19M 71.80M 56.67M 38.20M
Cost of revenue 5.53M -0.02M 0.99M 1.02M 0.85M
Total other income expense net -86.34M -7.11M 2.86M 2.85M -0.99M
Net income applicable to common shares - - - -49.63M -33.62M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 118.97M 69.56M 116.00M 121.98M 138.92M
Intangible assets 0.05M 0.54M 0.57M 0.77M 0.94M
Other current assets 2.79M 5.08M 18.99M 23.87M 25.91M
Total liab 225.61M 101.59M 70.53M 33.12M 27.71M
Total stockholder equity -106.65M -32.03M 45.48M 88.87M 111.21M
Other current liab 78.08M 9.22M 11.34M 8.25M 6.99M
Common stock 0.96M 0.52M 0.42M 0.41M 0.39M
Retained earnings -184.21M -110.43M -54.27M -49.63M -33.62M
Other liab - - - 1.43M 3.76M
Good will - -0.00M - - -
Other assets - -0.00M 1.67M 2.44M 1.71M
Cash 96.56M 26.92M 87.02M 87.31M 106.72M
Total current liabilities 120.73M 50.16M 30.70M 22.85M 13.91M
Current deferred revenue - 0.01M - - -
Net debt -42.23M 10.57M -87.02M -87.31M -106.72M
Short term debt 5.87M 5.31M - - -
Short long term debt total 54.33M 37.49M - - 10.04M
Other stockholder equity 249.16M 201.86M 99.33M 138.09M 144.44M
Property plant equipment - - - 3.20M 3.28M
Total current assets 111.51M 48.19M 106.38M 115.58M 133.00M
Net tangible assets - - - 88.10M 110.28M
Short term investments - 0.07M - - -
Net receivables 12.16M 15.71M 0.00M 4.00M 0.05M
Long term debt - - - - 10.04M
Inventory - 0.42M 0.37M 0.39M 0.32M
Accounts payable 32.86M 37.68M 19.36M 14.60M 6.92M
Accumulated other comprehensive income -172.55M -123.99M - - -
Non currrent assets other 1.05M 10.06M -7.95M -3.97M -4.22M
Non current assets total 7.46M 21.37M 7.95M 3.97M 4.22M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - - -1.35M -8.27M
Change to liabilities - - - 7.60M 1.27M
Total cashflows from investing activities 8.74M -7.73M - -1.79M -8.56M
Net borrowings - - - -0.03M 9.89M
Total cash from financing activities 145.59M 29.08M 37.27M 25.45M 111.67M
Net income -184.21M -110.43M -54.27M -49.63M -33.62M
Change in cash 69.65M -59.82M 0.18M -19.13M 69.85M
Begin period cash flow 26.92M 86.74M 86.55M 105.69M 35.84M
End period cash flow 96.56M 26.92M 86.74M 86.55M 105.69M
Total cash from operating activities -85.93M -81.61M -44.93M -47.63M -30.59M
Depreciation 5.20M 2.60M 1.62M 0.87M 0.88M
Other cashflows from investing activities -0.33M 0.13M - 0.00M 0.00M
Change to inventory 0.42M -0.04M 0.02M -0.07M 0.07M
Change to account receivables 2.81M -5.84M 3.84M -5.32M -0.46M
Sale purchase of stock - - - - 101.78M
Other cashflows from financing activities 68.33M 5.10M 39.04M 25.48M 111.76M
Change to netincome - - - -1.13M 1.14M
Capital expenditures 0.33M 0.54M 0.56M 0.53M 0.29M
Change in working capital 7.01M 17.31M 3.86M -5.39M -0.39M
Stock based compensation 3.58M 3.97M 2.22M 2.09M 0.94M
Other non cash items 82.49M 9.68M 1.65M 4.43M 1.60M
Free cash flow -86.26M -82.15M -45.49M -48.16M -30.88M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0RNK
Inventiva S.A.		 0.14
4.35%		 3.24 - - 10.69 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

50 rue de Dijon, Daix, France, 21121

33 3 80 44 75 00

https://inventivapharma.com

84

Name Title Year Born
Mr. Frederic Cren Co-Founder, CEO & Chairman 1966
Dr. Pierre Broqua Ph.D. Co-Founder, Chief Scientific Officer, Deputy CEO & Director 1962
Mr. Jean Volatier Chief Financial Officer 1964
Mr. Eric Duranson L.L.M. Gen. Counsel 1974
Ms. Nathalie Harroy Head of HR 1967
Dr. Irena Konstantinova Head of Biology & Pharmacology NA
Dr. Michael Cooreman Chief Medical Officer 1958
Mr. Jean-Paul Dutertre M.D. Head of Pharmacovigilance NA
Dr. Pierre Broqua Ph.D. Co-Founder 1962
Dr. Martine Zimmermann Pharm.D. Executive VP of Regulatory Affairs & Quality Assurance 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…